Abstract

Parkinson is one of the progressive neurodegenerative diseases. Various efforts are made in handling this disease, one of them is the utilization of plant extracts that have anti-Parkinson activity, for example, velvet bean (Mucuna pruriens L.). Changing the particle size of the extract into nanoscale particle is expected to increase its anti-parkinson activity. The research was conducted to synthesize silver-velvet bean (Mucuna pruriens L.) seed extract nanoparticles (AgMPn) and to evaluate its antiparkinson activity through the catalepsy test in mice. The research consisted of several stages i.e. extraction of velvet bean seed powder, synthesis and characterization of AgMPn, and catalepsy test of AgMPn. Velvet bean seed powder was extracted by maceration method using ethanol-water (1:1) at pH 3 adjusted with citric acid. AgMPn was synthesized by reacting the silver nitrate (AgNO3) solution with the extract of velvet bean seed for 40 min, dispersibility of solution during the reaction was controlled by using sonication and ultrasonic processor homogenizer. Characterization of AgMPn was done by using Fourier transform infrared (FT-IR), scanning electron microscopy-energy dispersive X-ray (SEM-EDX), and transmission electron microscopy (TEM). Catalepsy test was conducted on AgMpn at the doses of 5, 10, 15, 20 and 25 mg/kg body weight. The results of SEM-EDX and TEM showed that AgMPn formed aggregates with several shapes such as rectangle, oval, and spherical, with the average particle diameter was 36.5 nm. FT-IR spectra showed a band at 464.8 cm-1 absorbance area which is typical band indicated the interaction of Ag-O of AgMPn. Catalepsy test demonstrated that AgMPn at the doses of 5, 15, and 20 mg/kg body weight lowered the catalepsy symptoms in mice significantly, with the best dose was 5 mg/kg body weight.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call